In HNSCC, BRD4 recruits mediators and NF-κβ p65 to form super-enhancers at cancer stemness genes such as TP63, MET, and FOSL1, instead of MYC. Interestingly, the use of BET inhibitors disrupts the super-enhancers, eliminates cancer stem cells, and inhibits HNSCC invasive growth and metastasis [148]. The gene discussed is MET; the disease is cancer.